Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 16/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14840778 | 0.88 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL20775970 | 0.88 | CYP46A1 (0.81) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849013 | 0.85 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849067 | 0.83 | CYP46A1 (0.80) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840498 | 0.81 | CYP46A1 (0.69) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849031 | 0.80 | CYP46A1 (0.85) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849017 | 0.80 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849064 | 0.78 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840550 | 0.78 | CYP46A1 (0.80) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14848968 | 0.78 | CYP46A1 (0.80) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.